First patient implanted with Alphatec’s NEXoss nanostructure bio-active matrix


Alphatec Spine has announced the first clinical use of its NEXoss nanostructure bio-active matrix, a next generation synthetic bone graft indicated for use in posterolateral spine fusions in conjunction with bone marrow aspirate, autograft bone and appropriate hardware

The three-level posterior lumbar fusion procedure was performed by Joseph Stern, a neurosurgeon in private practice in Greensboro, USA. The patient was treated for progressive worsening of spondylolisthesis of L3-4 and L5-S1 with spinal stenosis and degenerative changes at L3-4, L4-5, and L5-S1 levels.

Stern chose Alphatec NEXoss as the fusion graft material based on the proven safety and effectiveness of the product technology.  He said “I am very pleased with the excellent handling properties of Alphatec NEXoss. The mixing and delivery system has been designed with the surgeon in mind and provides a very easy and effective way to deliver the graft both in open and minimally invasive surgery cases.” 

According to a company press release, NEXoss is composed of two unique patented technologies. The first is an engineered extracellular collagen bioscaffold that provides a physical structure for cell infiltration and attachment, and the second is osteoconductive nano-structured bone crystals that have similar composition, structure and size as human bone. These two technologies function together to provide an ideal environment for a natural bone growth solution. NEXoss is supported by in vitro and in vivo clinical data.

Last month, Alphatec announced the acquisition of exclusive US distribution rights to market the product under its own brand, Alphatec NEXoss. The product is FDA-cleared for commercial sale.